The number of men being prescribed testosterone jumped more than 75 percent, to 2.3 million, between 2009 and 2013. About 70 percent of these patients were between the ages of 40 and 64, the FDA said. AbbVie Inc's AndroGel, one of the most widely-used products, raked in sales of $934 million in 2014. Other products include Endo International Plc's Testim and Eli...
Feb 25- Antares Pharma Inc said its once-weekly testosterone injection met the main goal in an ongoing late-stage study in testosterone-deficient adult males. The U.S. Food and Drug Administration asked Antares last month for additional safety data on the drug, to be sold as QuickShot Testosterone, after a patient developed hives in a separate mid-stage...
Jan 13- Antares Pharma Inc said the U.S. Food and Drug Administration has asked for additional safety data on its testosterone drug after a patient developed hives in a mid-stage trial. The FDA has become more cautious about approving testosterone drugs after it found late last year that more than a fifth of the patients prescribed such drugs did not get their...
Jan 13- Antares Pharma Inc said the U.S. Food and Drug Administration has asked for additional safety data on its testosterone drug after a patient developed hives in a mid-stage trial. Hives is an allergic skin reaction that causes red, itchy bumps on the skin. The FDA has asked for data on 350 patients exposed to the drug, QuickShot Testosterone.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Cramer makes the call on viewer favorites.
Oct 08- Fitch Ratings has upgraded Atrium European Real Estate Limited's Long-term Issuer Default Rating and senior unsecured rating to' BBB-' from' BB+'. The Outlook on the IDR is Stable.
EWING, N.J.-- Antares Pharma Inc. said Wednesday that it plans to sell 12.5 million shares of its stock for $4 per share, raising about $47 million after expenses. Shares of Antares fell 37 cents, or 8.4 percent, to $4.03 in afternoon trading Wednesday. It has traded between $1.51 and $5.58 in the last 12 months.
U.S. stocks advanced on Wednesday after stronger-than-expected employment and service-sector data in the United States. But a gloomier outlook in China and Europe weighed on commodity prices and hit energy and materials shares. **SAREPTA THERAPEUTICS INC, $41.60, up 177 pct.
U.S. stocks rose on Wednesday after stronger-than-expected employment and service-sector data in the United States, but a gloomier outlook in China and Europe weighed on commodity prices and hit energy and materials shares. **SAREPTA THERAPEUTICS INC, $40.65, up 171 pct. **HEWLETT-PACKARD CO, $15.67, down 8.4 pct.
**SAREPTA THERAPEUTICS INC, $40.19, up 168 pct. **BIOLASE INC, $2.11, up 27 pct. The company said health regulators in Europe and the United States approved its laser device for use in soft tissue surgery, teeth whitening, and pain therapy.
The Nasdaq Composite Index rose 0.37 percent. **SAREPTA THERAPEUTICS INC, $30.30, up 102 pct. **INTERMUNE INC, $9.74, up 10 pct.
Oct 3- Antares Pharma Inc:. *Announces pricing of public offering of common stock. *Says public offering of 12.5 million common shares priced at $4.00 per share.
EWING, N.J.-- Shares of Antares Pharma Inc. fell more than 9 percent in after-hours trading Tuesday after the drugmaker said it plans to sell more of its stock. The company also said Tuesday that it received a $750,000 milestone payment from its partner Pfizer Inc.. Shares of Antares Pharma fell 41 cents, or 9.3 percent, to $3.99 in aftermarket trading.
EWING, N.J.-- Antares Pharma Inc. said Tuesday it received a $750,000 milestone payment from its partner Pfizer Inc.. In December 2011 Antares licensed drug delivery technology to Pfizer. Shares of Antares Pharma rose 12 cents, or 2.8 percent, to $4.40 on Tuesday.
Stocks ended mixed on Monday as investors cast a wary eye on rising interest rates ahead of the Fed's two day meeting this week.
How Big A Deal Is A Big Deal? Monday morning is traditionally the time we get the most merger and acquisition news - hence the often used (and overused) term “Merger Monday”. But how big a deal should we make over a deal?
The chief executive of Symantec told CNBC that the planned $830 million acquisition of Altiris will boost the security software maker's long-term sales.